Physician profile
Cory Logan
NPI 1215384219
$4,672.06
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $823 · 2022: $1,188 · 2023: $1,810 · 2024: $851.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,660.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $606.10 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $502.25 | 2021-2024 | Freestyle Libre 3 |
| Abbvie INC. | $430.27 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $334.21 | 2021-2024 | Jardiance |
| Lilly USA, LLC | $314.25 | 2021-2024 | Mounjaro, Jardiance, Emgality |
| Pfizer INC. | $303.28 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $285.54 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $211.28 | 2021-2024 | Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $188.78 | 2021-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Janssen Pharmaceuticals, INC | $187.90 | 2021-2023 | Xarelto |
| Astellas Pharma US INC | $154.52 | 2021-2024 | Veozah, Myrbetriq |
| Amgen INC. | $140.60 | 2021-2024 | Evenity, Prolia, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $127.23 | 2021-2023 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $120.33 | 2021-2023 | |
| Xeris Pharmaceuticals, INC. | $85.70 | 2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $75.10 | 2022-2023 | Austedo Xr, Austedo |
| Merck Sharp & Dohme LLC | $56.52 | 2023 | Dificid, Belsomra |
| Idorsia Pharmaceuticals US INC | $41.57 | 2022-2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $37.73 | 2022 | |
| Amarin Pharma, INC. | $36.97 | 2021 | |
| Exact Sciences Corporation | $36.06 | 2023 | Cologuard Collection Kit |
| Genentech USA, INC. | $35.77 | 2021 | |
| Biogen, INC. | $34.47 | 2021 | |
| Nestle Healthcare Nutrition INC. | $33.42 | 2022-2023 | |
| Shield Therapeutics INC | $32.86 | 2023 | Accrufer |
| Supernus Pharmaceuticals, INC. | $32.68 | 2023 | Qelbree, Xyosted |
| E.R. Squibb & Sons, L.L.C. | $30.79 | 2023 | Eliquis |
| Dexcom, INC. | $29.59 | 2024 | Dexcom G6 Transmitter |
| Inari Medical, INC. | $29.24 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Kowa Pharmaceuticals America, INC. | $25.81 | 2021-2022 | |
| Inspire Medical Systems, INC. | $20.23 | 2024 | Inspire |
| Halozyme INC | $20.09 | 2023 | |
| Arbor Pharmaceuticals, INC. | $17.07 | 2021 | |
| Sumitomo Pharma America, INC. | $14.46 | 2024 | Gemtesa |
| Azurity Pharmaceuticals, INC. | $13.32 | 2024 | Horizant |
| Sunovion Pharmaceuticals INC. | $13.31 | 2022 | |
| Eisai INC. | $12.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cory Logan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.